清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

ADAM17-Deficient Pluripotent Stem Cell-Derived Natural Killer Cells Possess Improved Antibody-Dependent Cellular Cytotoxicity and Antitumor Activity

抗体依赖性细胞介导的细胞毒性 脱颗粒 淋巴因子激活杀伤细胞 细胞生物学 Janus激酶3 细胞毒性T细胞 白细胞介素12 白细胞介素21 NK-92 抗体 化学 生物 癌症研究 免疫学 受体 体外 单克隆抗体 生物化学
作者
Kenta Yamamoto,Robert Blum,Dan S. Kaufman
出处
期刊:Blood [Elsevier BV]
卷期号:136 (Supplement 1): 2-2 被引量:6
标识
DOI:10.1182/blood-2020-137766
摘要

Antibody-dependent cellular cytotoxicity (ADCC) is a key pathway that mediates natural killer (NK) cell cytotoxicity against antibody-opsonized target cells. This process helps mediate the therapeutic efficacy of anti-tumor antibodies. On NK cells, ADCC occurs via engagement of antibody-coated target cells with activating receptor FcγRIIIa, or CD16a, leading to proinflammatory cytokine upregulation, degranulation, and target cell death. Upon cellular activation, the CD16a ectodomain is cleaved from the NK cell surface by A Disintegrin and Metalloprotease-17 (ADAM17). Cleavage of the ectodomain prevents further antibody binding and signaling through CD16a, which dampens NK cell activity. Blocking activation-induced ADAM17-mediated CD16a cleavage has been previously demonstrated to augment ADCC activity and provides a novel strategy to improve efficacy of therapeutic antibodies in combination with adoptive transfer of engineered NK cells. To further define the ability of ADAM17 to regulate NK cell activity, we have generated and characterized ADAM17-deficient (ADAM17-KO) NK cells derived from CRISPR/Cas9-modified human induced pluripotent stem cells (iPSCs). ADAM17-KO iPSCs successfully differentiate into hematopoietic progenitor cells, then to NK cells that uniformly express typical NK cell surface markers including CD56, CD94, NKG2D, NKp44, and NKp46. ADAM17-KO iPSC-NKs are functional and kill K562 erythroleukemia cells comparable to wildtype iPSC-derived NK cells (WT iPSC-NK cells) and healthy donor-derived peripheral blood NK cells (PB-NK cells) in vitro. Surprisingly, upon differentiation, ADAM17-KO iPSC-NK cells express ~20% lower CD16a surface expression compared to WT iPSC-NK cells, but stably retain CD16a expression after enrichment for CD16a+ cells and over 6 weeks of expansion in culture. WT iPSC-NKs and PB-NKs rapidly lose CD16a surface expression upon stimulation with phorbol esters, while ADAM17 KO iPSC-NK cells maintain over 90% CD16a expression after this stimulation. Additionally, a significantly higher proportion of ADAM17-KO iPSCs express TNF-α (71%) and CD62L (L-Selectin) (36%) - two other known ADAM17 substrates, on the cell surface after stimulation with phorbol esters for 4 hours compared to WT iPSC-NK (7% TNF-α+, 2% L-Selectin+) and PB-NK (2% TNF-α+, 1% L-Selectin+). CD16a+ ADAM17-KO iPSC-NK cells mediate increased CD107a (45%) and IFNγ (39%) expression when co-incubated with RAJI B-lymphoma cells in the presence of the anti-CD20 antibody rituximab, compared to CD16a+ WT iPSC-NK (32% CD107a+, 11% IFNγ) and PB-NK (37% CD107a+, 7% IFNγ) cells. Similarly, CD16a+ ADAM17-KO iPSC-NK cells upregulate increased CD107a (29%) and IFNγ (42%) expression when co-incubated with CAL27 squamous cell carcinoma cells in the presence of the anti-EGFR antibody cetuximab, compared to CD16a+ WT iPSC-NK (12% CD107a+, 8% IFNγ) and PB-NK (14% CD107a+, 6% IFNγ). Long-term (24 hour) cytotoxicity assay against RAJI cells in the presence of rituximab demonstrates higher cytotoxicity in CD16a+ ADAM17-KO iPSC-NK cells compared to CD16a+ WT iPSC-NK and CD16a+ PB-NK cells over time (see associated figure). In vivo studies to determine the therapeutic efficacy of ADAM17-KO iPSC-NK cells compared to WT iPSC-NK and PB-NK cells are ongoing. Together, these studies demonstrate ADAM17-KO iPSC-NK cells derived from a renewable source of gene-edited iPSCs possess enhanced ADCC potential, and provide a promising candidate to be used for standardized, off-the-shelf NK cell-based therapies in conjunction with therapeutic antibodies. Figure Disclosures Blum: Fate Therapeutics: Current Employment. Kaufman:Fate Therapeutics: Consultancy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
lovesxj941完成签到,获得积分10
8秒前
许若南完成签到 ,获得积分10
30秒前
听话的尔竹完成签到,获得积分10
48秒前
飞云完成签到 ,获得积分10
1分钟前
害羞的雁易完成签到 ,获得积分10
1分钟前
宏韬完成签到 ,获得积分10
1分钟前
阿俊1212完成签到 ,获得积分10
1分钟前
1分钟前
体贴的冷风完成签到 ,获得积分10
1分钟前
miaorunquan完成签到,获得积分0
1分钟前
1分钟前
2分钟前
2分钟前
2分钟前
qiqi完成签到 ,获得积分10
2分钟前
2分钟前
超级诗桃完成签到,获得积分10
2分钟前
如我所愿完成签到 ,获得积分10
2分钟前
阿连完成签到,获得积分10
2分钟前
YF是杨芳完成签到 ,获得积分10
2分钟前
Maestro_S的应助被东风采纳,获得10
2分钟前
可爱沛蓝完成签到 ,获得积分10
2分钟前
激动的元瑶完成签到 ,获得积分10
2分钟前
Maestro_S的应助被东风采纳,获得10
2分钟前
msn完成签到 ,获得积分10
3分钟前
夏日随笔完成签到 ,获得积分10
3分钟前
丰富的德天完成签到 ,获得积分10
3分钟前
3分钟前
3分钟前
仔仔完成签到 ,获得积分10
3分钟前
Wywy完成签到 ,获得积分10
3分钟前
薛定谔的猫完成签到 ,获得积分10
3分钟前
4分钟前
记上没文献了完成签到 ,获得积分10
4分钟前
4分钟前
4分钟前
林韵悠扬完成签到 ,获得积分10
4分钟前
CQNU破产之人完成签到 ,获得积分20
4分钟前
思源的应助被东风采纳,获得10
4分钟前
李爱国的应助被东风采纳,获得10
4分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190312
求助须知:如何正确求助?哪些是违规求助? 9577402
关于积分的说明 21852440
捐赠科研通 7788867
什么是DOI,文献DOI怎么找? 3436315
关于科研通互助平台的介绍 2560109
邀请新用户注册赠送积分活动 2482945